血清ADA联合GLB、CREA、β2-MG、HGB在初诊多发性骨髓瘤中的临床意义  

Clinical Significance of Serum ADA Combined with GLB,CREA,β2-MG and HGB in Newly Diagnosed Multiple Myeloma

作　　者：钱晗 袁鸿玲 张婷 杨渝伟[2] 俸家富[2] QIAN Han;YUAN Hong-Ling;ZHANG Ting;YANG Yu-Wei;FENG Jia-Fu(Department of Clinical Laboratory,The First Affiliated Hospital of Chengdu Medical College,Chengdu 610500,Sichuan Province,China;Department of Clinical Laboratory,Mianyang Central Hospital,Mianyang 621000,Sichuan Province,China)

机构地区：[1]成都医学院第一附属医院检验科,四川成都610500 [2]绵阳市中心医院检验科,四川绵阳621000

出　　处：《中国实验血液学杂志》2024年第3期780-788,共9页Journal of Experimental Hematology

基　　金：四川省科技厅科技支撑计划资助项目(2019YJ0701);成都市医学科研课题项目(2023171)。

摘　　要：目的:研究血清腺苷脱氨酶(ADA)联合球蛋白(GLB)、肌酐(CREA)、β2-微球蛋白(β2-MG)、血红蛋白(HGB)对多发性骨髓瘤(MM)的初筛作用,减少MM的漏诊及误诊。方法:回顾性分析2018年4月至2021年12月成都医学院第一附属医院血液科收治的62例初诊多发性骨髓瘤(NDMM)患者的资料,并以33例良性血液病患者和30例健康体检者作为对照组。用TCGA和GTEx数据库分析ADA在泛癌中的表达。收集受试者的一般资料及实验室检测指标,比较各组ADA活性及其他实验室指标水平的差异。分析血清ADA活性与NDMM患者临床资料的关系。比较NDMM患者化疗前后ADA活性的变化以及不同DS、ISS分期NDMM患者中ADA活性的差异。多因素Logistic回归分析NDMM发生的危险因素。采用ROC曲线评价ADA及其联合其他实验室指标对MM的诊断效能。生物信息学分析ADA的共表达网络和富集途径。结果:TCGA数据库中有14种癌组织中ADA水平显著上调,TCGA联合GTEx数据库中ADA在11种癌症中高表达。NDMM组外周血清ADA、GLB、UA、CysC、β2-MG水平明显高于良性血液病组及健康对照组(P<0.05),ALB、A∶G明显低于良性血液病组及健康对照组(P<0.001)。不同ADA活性水平的NDMM患者的DS分期(P=0.036)、ISS分期(P=0.019)、CREA(P=0.036)、UA(P=0.034)、β2-MG(P=0.019)水平具有统计学差异。NDMM患者初次化疗后ADA活性及β2-MG浓度有所下降(P<0.01)。不同DS分期和ISS分期患者比较结果显示,DS I+II期患者ADA活性明显低于Ⅲ期患者(P<0.05),ISS I+II期患者ADA活性也明显低于Ⅲ期患者(P<0.01)。多因素Logistic回归分析结果显示,GLB增高、ADA活性增加、CREA增高、β2-MG增高、HGB降低是NDMM的独立危险因素。ADA诊断MM的曲线下面积为0.847,其联合GLB、CREA、β2-MG、HGB诊断MM的曲线下面积为0.940。共表达网络和富集途径分析结果显示,ADA与20种蛋白质结合,并与嘌呤代谢、嘧啶代谢、烟酸和烟酰胺代谢通路显�Objective:To investigate the role of serum adenosine deaminase(ADA)combined with globulin(GLB),creatinine(CREA),β2-microglobulin(β2-MG)and hemoglobin(HGB)in the initial screening of multiple myeloma(MM),in order to reduce missed diagnosis and misdiagnosis of MM.Methods:A retrospective analysis was performed on 62 newly diagnosed multiple myeloma(NDMM)patients who were admitted to the Department of Hematology of the First Affiliated Hospital of Chengdu Medical College from April 2018 to December 2021,and 33 patients with benign hematologic diseases and 30 healthy subjects were selected as the control group.The expression of ADA in pan-cancer was analyzed using TCGA and GTEx databases.The general data and laboratory indicators of the subjects were collected,and the differences of ADA activity and other laboratory indicators in each group were compared.The relationship between serum ADA activity and clinical data of NDMM patients was analyzed.The changes of ADA activity before and after chemotherapy in NDMM patients and the differences of ADA activity in NDMM patients with different DS and ISS stages were compared.Multivariate logistic regression was used to analyze the risk factors of NDMM.The receiver operating characteristic(ROC)curve was used to evaluate the diagnostic efficacy of ADA and other laboratory indicators in MM.Bioinformatics method was used to analyze the co-expression networks and enrichment pathways of ADA.Results:ADA level was significantly upregulated in tissues of 14 types of cancer in TCGA database,and ADA was highly expressed in 11 types of cancer in TCGA combined with GTEx databases.The serum levels of ADA,GLB,uric acid(UA),cystatin C(CysC)andβ2-MG in the NDMM group were significantly higher than those in benign hematologic disease group and healthy control group(P<0.05),while the levels of ALB and the value of albumin to globulin ratio(A∶G)in the NDMM group were significantly lower than those in the other two groups(P<0.001).There were significant differences in DS stage(P=0.036),ISS st

关 键 词：多发性骨髓瘤 腺苷脱氨酶 疗效评价 监测疾病进展 诊断 

分 类 号：R733.3[医药卫生—肿瘤]